Hold-Time and Shear: Hidden Contributors to Drift



Hold-Time and Shear: Hidden Contributors to Drift

Published on 29/11/2025

Hold-Time and Shear: Hidden Contributors to Drift in Biosimilar Analytical Comparability

The development of biosimilars presents unique challenges in ensuring analytical comparability with reference products. Key concepts such as biosimilar analytical comparability, cqa mapping, and fingerprint analytics play an essential role in addressing these challenges. This guide provides a comprehensive step-by-step tutorial on how to monitor process drift caused by hold-time and shear stress during the manufacturing process, ensuring that biosimilars meet regulatory expectations.

Understanding Biosimilar Analytical Comparability

Biosimilar analytical comparability is the process by which a biosimilar is shown to be similar in quality, safety, and efficacy to an already approved reference biologic product. It involves rigorous testing and validation procedures to assess critical quality attributes (CQAs) that influence the therapeutic effect, immunogenicity, and overall patient safety.

The cqa mapping framework is critical in this context, as it defines the parameters that must be monitored throughout the lifecycle of the product. By evaluating these attributes systematically, companies can identify potential variances that may occur during production, particularly during critical phases like hold-time and shear application.

Key Components of Process Drift: Hold-Time and Shear

Process drift refers to the gradual change in process performance over time, which can adversely affect the quality attributes of biosimilars. Two significant factors contributing to process drift are hold-time and shear.

1. Hold-Time Impact

Hold-time represents the duration during which a biological substance is maintained in a specific state before moving to the next step in the manufacturing process. During hold-time, the potential for biochemical changes increases, which can result in alterations to CQAs. Regulatory agencies such as the FDA and EMA emphasize the importance of characterizing these changes to ensure stability and efficacy.

  • Assessment of Stability: It is crucial to evaluate the stability of the biological material during hold-time, particularly concerning temperature, pH, and other environmental factors.
  • Analytical Techniques: Employ analytical methods such as fingerprint analytics to monitor changes during hold-time and establish acceptable limits.
  • Statistical Analysis: Utilize statistical tools to analyze stability data and uncover trends that may indicate potential process drift.

2. Shear Stress Influence

Shear stress can occur during mixing, pumping, or processing operations and can significantly impact the structural integrity and function of biological molecules. Understanding how shear stress affects CQAs is critical for maintaining biosimilar equivalence. Key activities include:

  • Characterization of Shear Effects: Perform extensive characterization studies to evaluate how different shear rates affect the stability of the product.
  • Equipment Validation: Ensure that equipment used in production is validated for shear stress tolerance and consistently operates within defined parameters.
  • Design of Experiments (DOE): Implement a DOE approach to systematically investigate the relationship between shear rates and process outcomes.

Process Drift Monitoring Strategies

To effectively monitor process drift attributable to hold-time and shear, a robust strategy is essential. This involves defining clear metrics for evaluation and establishing a feedback loop for continuous improvement.

1. Define CQAs and CPPs

Establish a comprehensive list of critical quality attributes (CQAs) and critical process parameters (CPPs) associated with the production of biosimilars. This will facilitate the identification of potential drift early in the process.

2. Implement Real-Time Monitoring

Implementing real-time monitoring through advanced analytical tools allows for immediate detection of any process drift, especially those due to hold-time and shear. This responsiveness is crucial in making necessary adjustments without compromising product quality.

  • Inline Sensor Technology: Utilize inline sensors for continuous monitoring of parameters such as temperature and viscosity.
  • Data Integration: Integrate data from various monitoring devices to create a comprehensive view of the process in real-time.

3. Establish a Change Control Process

A formalized change control process is imperative for managing deviations in CQAs and responding to observed drifts timely. The process should involve:

  • Documenting Changes: Ensure all changes in process parameters, including hold-time and shear settings, are documented meticulously.
  • Impact Assessment: Conduct a thorough assessment of any changes and their potential impact on CQAs through equivalence testing.

Bridging Justifications and Equivalence Testing

Regulatory agencies require extensive documentation to justify bridging between the reference product and the biosimilar. This section provides insights into how to develop effective bridging justifications and conduct equivalence testing.

1. Framework for Bridging Justifications

Bridging justifications are essential to connect data from the biosimilar’s production process with the reference product. It is vital to articulate these justifications clearly to align with regulatory expectations, including those outlined in the Q5E comparability guideline.

  • Data Compilation: Compile data from analytical comparability studies, including stability, immunogenicity, and efficacy results.
  • Key Comparisons: Clearly outline how comparability has been demonstrated through both analytical and clinical evaluations.

2. Equivalence Testing Approaches

Equivalence testing is a critical component when demonstrating that the biosimilar is therapeutically equivalent to the reference product. Testing methodologies should encompass:

  • Statistical Approaches: Employ statistical models suitable for data analysis, providing evidence of equivalence.
  • Regulatory Alignment: Ensure that the testing plan is in harmony with FDA/EMA guidance to minimize discrepancies during review.

Integrating PPQ and CPV into Biosimilar Development

Robust process performance qualification (PPQ) and Continued Process Verification (CPV) strategies are critical in demonstrating that the biosimilar manufacturing process consistently produces a product that meets predetermined specifications. This includes:

1. Developing a Comprehensive PPQ Plan

A comprehensive PPQ plan should detail the evaluation of the production process under various conditions, including extreme scenarios to understand potential variances caused by hold-time and shear stress.

  • Process Mapping: Create a detailed process map identifying all operations and their associated risks.
  • Risk Assessment: Perform risk assessments to prioritize areas needing focused evaluation during PPQ.

2. Establishing a CPV Framework

Establish a CPV framework that allows for ongoing monitoring and verification of process consistency. The CPV strategy should include:

  • Routine Monitoring: Incorporate routine monitoring of CQAs and CPPs with predefined acceptance criteria.
  • Trend Analysis: Implement trend analysis techniques that facilitate early detection of deviations related to hold-time and shear effects.

Documenting Results for Regulatory Submissions

Once analytical comparability studies are completed, documentation is crucial for successful submissions to regulatory authorities. It is essential to compile all findings comprehensively.

1. Compiling Dossier-Ready Summaries

A dossier ready for submission should encapsulate all study data, methodologies, and results. This should be presented clearly to facilitate regulatory review, highlighting key findings related to drift monitoring.

  • Executive Summary: Provide a concise executive summary outlining the objectives, methods, and results of the study.
  • Supporting Data: Attach all relevant analytical comparability data, including statistical analyses and method validations.

2. Aligning with Regulatory Expectations

Ensure the documentation aligns with the specific language stipulated in Q6B specifications and any additional guidelines pertinent to the biosimilar submission processes. This alignment increases the likelihood of a smooth review process and subsequent approval.

Conclusion

In the challenging field of biosimilar development, understanding and mitigating the impact of hold-time and shear on process drift is critical. By diligently applying sound practices in biosimilar analytical comparability, along with effective cqa mapping and fingerprint analytics, pharmaceutical professionals can navigate these complexities successfully. This structured approach not only enhances compliance with regulatory expectations from entities such as the FDA and EMA but also promotes a sustainable quality strategy throughout the biosimilar lifecycle.